T1	p 93 132	advanced epithelial ovarian carcinoma .
T2	p 296 403	patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen . PATIENTS
T3	p 416 464	Patients with bidimensionally measurable disease
T4	p 638 642	with
T5	p 982 1033	total of 226 patients were evaluable for response .
T6	p 1901 1958	patients receiving topotecan at relapse of ovarian cancer
T7	i 62 89	topotecan versus paclitaxel
T8	i 265 292	topotecan versus paclitaxel
T9	i 484 499	topotecan ( 1.5
T10	i 511 515	/day
T11	i 529 548	or paclitaxel ( 175
T12	i 560 564	/day
T13	i 657 664	therapy
T14	i 1279 1289	paclitaxel
T15	i 1509 1519	paclitaxel
T16	i 1605 1614	Topotecan
T17	i 1676 1686	paclitaxel
T18	i 1920 1929	topotecan
T19	o 16 24	survival
T20	o 685 792	European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire
T21	o 824 832	symptoms
T22	o 870 971	pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) .
T23	o 1125 1153	EORTC QOL-30 questionnaire .
T24	o 1180 1206	median time to progression
T25	o 1397 1412	median survival
T26	o 1651 1672	efficacy and survival
T27	o 1707 1775	non-cumulative haematological toxicity . Non-haematological toxicity
T28	o 1817 1840	long-term survival rate